Predicting Outcomes and Monitoring Disease in Patients With Multiple Myeloma

Abstract: Multiple myeloma (MM) is a clonal plasma cell dyscrasia and the most common form of primary bone marrow cancer. Nearly 35,000 new cases of MM […]

Novel Approaches to the Treatment of Multiple Myeloma

Abstract: The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly […]

Optimizing the Benefits of BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

H&O  Why is the B-cell maturation antigen (BCMA) a good target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? SL  BCMA is an important […]

Best Practices for the Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma

Abstract: Therapeutic advances in multiple myeloma have led to durable, deep remissions in a subset of patients. However, outcomes of patients achieving a complete response are not […]

Advances in the Development of Vaccines and Other Immunotherapies for Multiple Myeloma 

  H&O  What types of immune-based therapies are in development for multiple myeloma? DA Immunotherapy is an important area in multiple myeloma, and this field encompasses […]

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma Is Ready for Prime Time 

  Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]

Hem/Onc News

Selinexor Approved for Multiple Myeloma On July 3, the US Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm) in combination with dexamethasone […]

A Clinician’s Perspective of Treatment of Relapsed or Refractory Multiple Myeloma

Click the “Download PDF” button to read Dr. Paul G. Richardson’s perspective on treatment of relapsed or refractory multiple myeloma.      

Immune-Mediated Hemolytic Anemia and Thrombocytopenia in Clonal B-Cell Disorders: A Review 

  Abstract: Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia purpura (ITP) have been associated with B-cell lymphoproliferative disorders. Here, we review the epidemiology, pathogenesis, diagnosis, and […]

Monitoring Multiple Myeloma

  Abstract:  Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated plasma cells. MM is a slowly growing, […]

Incorporating Monoclonal Antibodies Into the Management of Multiple Myeloma

  H&O  How do monoclonal antibodies work? TM  Monoclonal antibodies are immunoglobulins (Igs) that are generated and manufactured to target a specific antigen present on a […]

The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma

  Abstract:  Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments. Certain molecular abnormalities confer […]

The Role of Autologous Stem Cell Transplant in Patients With Multiple Myeloma

  H&O  What are the clinical characteristics of multiple myeloma? JM  Multiple myeloma has historically been defined by 4 clinical characteristics: elevated calcium, renal deficiency, anemia, […]

Use of Genetic Markers in Multiple Myeloma

  H&O  In what ways is multiple myeloma a genetically heterogeneous disease? RF  In an editorial written several years ago, I referred to this disease as […]